Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
SAN DIEGO -- Intravenous ravulizumab (Ultomiris) yielded clinically meaningful reductions in IgA nephropathy-related proteinuria in a small, mid-stage trial. The 43 patients treated with ravulizumab ...
East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class ...
The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
MedPage Today on MSN
FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No.
Agency raised questions about avacopan's pivotal trial data and concerns of hepatotoxicity ...
(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results